pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 493
- Drugs
- 98
- Patents
- 837
Hyperpolarized Xe129
Phase 2 · small molecule · Pulmonary Artery Hypertension
Hyperpolarized Xe129 for Pulmonary Artery Hypertension is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Internal code Pro00113235
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Regeneron UK Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Pulmonary Artery Hypertension
- Status
- terminated
- Trials
- 1